# An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours

> **NCT02236910** · PHASE2 · UNKNOWN · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 66 (actual)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **OTHER:** Lu-DOTA-TATE

## Key facts

- **NCT ID:** NCT02236910
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-07
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02236910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02236910, "An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02236910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*